InvestorsHub Logo
Followers 22
Posts 3630
Boards Moderated 0
Alias Born 07/20/2006

Re: None

Friday, 06/26/2015 4:20:03 PM

Friday, June 26, 2015 4:20:03 PM

Post# of 20689
Momenta Pharmaceuticals (NASDAQ:MNTA)‘s stock had its “buy” rating reissued by analysts at Brean Capital in a research report issued to clients and investors on Friday. They currently have a $31.00 target price on the biotechnology company’s stock. Brean Capital’s price objective points to a potential upside of 34.90% from the stock’s previous close. June 26, 2015

http://www.dakotafinancialnews.com/momenta-pharmaceuticals-given-buy-rating-at-brean-capital-mnta/224340/